Ulcerative colitis- real world study for the effects of biologics, anti-TNF alpha- golimumab in remission- induction and maintenance- (UC- BINGO) study

Ulcerative colitis- real world study for the effects of biologics, anti-TNF alpha- golimumab in remission- induction and maintenance- (UC- BINGO) study - UC- BINGO study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026844

Enrollment

Registered

2017-06-01

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: UC- patients whose age is 15 years old and more, and 70 years ld and less. UC- patients refractory to conventional therapy UC- patiens refractory to infliximab and/ or adalimumab

Exclusion criteria

Exclusion criteria: Patients who has contraindication of golimumab Patients in pregnancy and lactation period Patients who has and had malignancy Patients who don nott have informed conents Patients determined not to be suitable for this study by physicians

Design outcomes

Primary

Measure	Time frame
Clinical response rate at week 6	—

Countries

Japan

Contacts

Public ContactSHINGO KATO

Saitama Medical University, Saitama Medical Center Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results